相关实验视频

Updated: Jun 20, 2026

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

准备,评估和生物信息学研究氨酸修饰的金赛诺化物Rb1自组装纳米颗粒用于治疗心血管疾病

Lixin Du¹, Yifei Xiao¹, Qidong Wei¹

¹School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.

Molecules (Basel, Switzerland)

|September 28, 2024

概括

用氨酸修饰的金丝诺酸Rb1纳米颗粒 (HA@GRb1@CS NPs) 经过优化和制备,显示出稳定的质量和强大的抗炎和抗氧化作用. 这些纳米粒子为与炎症和氧化应激有关的心血管疾病 (CVD) 提供了一个有前途的治疗策略.

科学领域:

纳米技术纳米技术
药理学药理学是指药理学的学科.
生物医学工程生物医学工程

背景情况:

心血管疾病 (CVD) 往往会因炎症和氧化压力而恶化.
金色化物Rb1 (GRb1) 具有治疗潜力,但其传递需要优化.
自组装纳米粒子为药物输送提供了一个有前途的平台.

研究的目的:

为了优化氨酸修饰的金氏化物Rb1自组装纳米粒子 (HA@GRb1@CS NPs) 的制备.
描述和评估HA@GRb1@CSNP的体外性能.
研究HA@GRb1@CSNP在治疗炎症和氧化应激相关心血管疾病中的治疗机制.

主要方法:

使用Plackett-Burman和Box-Behnken设计优化纳米粒子制备.
综合物理特征 (TEM,FTIR,XRD,DSC) 和体外评估 (稳定性,药物释放).
评估H9c2和RAW264.7细胞系的抗炎和抗氧化活性,并补充了生物信息学分析.

主要成果:

优化的HA@GRb1@CSNP的粒子大小为126.4nm,泽塔电位为36.8mV,PDI为0.243.3mV.
在体外研究证实了持续的药物释放,减少氧化损伤 (MDA,增加SOD) 和强大的自由基清除 (DPPH,ABTS+).
观察到明显抑制炎症因素 (NO,IL-6),以及生物信息学识别的治疗途径.

结论:

HA@GRb1@CS NPs表现出稳定的质量和显著的抗炎和抗氧化特性.
这些纳米颗粒代表了一种可行的治疗剂,用于控制心血管疾病中的炎症和氧化应激.
潜在的机制包括准调节亡,自和动脉硬化的主要途径.

关键词:

生物信息学是一种生物信息学.心血管疾病心血管疾病人参化物 Rb1 这是一种炎症炎症炎症炎症.氧化应激是一种氧化应激.自组装的纳米粒子.

更多相关视频

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...